AVM Biotechnology

AVM Biotechnology:
a National Institute of Health 2024 Innovation Company; National Cancer Institute 2023 Showcase Company; NIH/NIDDK 2022 Showcase Company

AVM was highlighted as a Company to Watch in 2023 by Life Science Nation.

Companies to Watch 2023 By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series For the past ten years, Life Science Nation (LSN) has built a global partnering platform that matches s…

AVM Biotechnology has received a $2 M Phase II SBIR grant from the National Cancer Institute to further the company’s clinical trial treating R/R NHL/Leukemia. This is additional validation of the important work we are doing developing AVM0703 for the treatment of cancer.

https://www.businesswire.com/news/home/20220614005414/en/AVM-Biotechnology-Awarded-2-Million-National-Cancer-Institute-SBIR-Phase-II-Grant-from-the-National-Institutes-of-Health-to-Advance-AVM0703-in-Cancer